CD274 and cholangiocarcinoma: From the other hand, next-generation and exome sequencing studies found that 10%~15% of cholangiocarcinoma patients had DNA repair mutations[53], and 40% of cholangiocarcinoma patients had positive programmed cell death receptor 1 (PDL1) expression[54], who might be the potential beneficiaries of immunotherapies.